Caplin Point Lab spurts 7.8% in two days

Caplin Point Laboratories rose 3.77% at Rs 271.45 at 11:10 IST on BSE, with the stock extending Thursday's 3.93% gains triggered by the company commencing additional line of production at its Pondicherry plant.

Meanwhile, the S&P BSE Sensex was down 49.46 points or 0.19% at 25,323.29.

On BSE, so far 6,374 shares were traded in the counter as against average daily volume of 14,564 shares in the past one quarter.

The stock hit a high of Rs 274.05 and a low of Rs 266.15 so far during the day. The stock had hit a record high of Rs 287 on 7 July 2014. The stock had hit a 52-week low of Rs 53 on 1 October 2013.

The stock had outperformed the market over the past one month till 10 July 2014, jumping 47.01% compared with Sensex's 0.82% fall. The scrip had also outperformed the market in past one quarter, surging 50.47% as against Sensex's 11.7% rise.

The small-cap company has equity capital of Rs 15.11 crore. Face value per share is Rs 10.

Shares of Caplin Point Laboratories have risen 7.84% in two trading sessions from a recent low of Rs 251.70 on 9 July 2014, after the company during market hours on Thursday, 10 July 2014, said it has commenced additional line of production at its Pondicherry plant. The stock had risen 3.93% to settle at Rs 261.60 on Thursday, 10 July 2014.

Caplin Point Laboratories said that the company's plant at Pondicherry has commenced its additional line of production in the area of suppositories which is unique in its feature which very few pharma companies have. This will now enable export of these products to semi regulated and non regulated markets which includes Dominican Republic, Guatemala, Nicaragua, El Salvador, Honduras, in Latin American countries & Angola, Mali in West African countries, Caplin Point said.

Caplin Point Laboratories' consolidated net profit surged 109.4% to Rs 7.10 crore on 43.4% growth in net sales to Rs 41.40 crore in Q3 March 2014 over Q3 March 2013.

Caplin Point Laboratories currently has three fully functioning facilities and one more facility in the pipeline, capable of manufacturing a wide range of dosage forms and products catering to all segments of the pharmaceutical industry.

Powered by Capital Market - Live News